Summary

Organization name

Profile

Poniard Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

In April 2006, they successfully completed a $65 million financing, which positioned them to expand clinical development of their lead product candidate, picoplatin, and focus their resources on building a diverse oncology pipeline through in-house research and in-licensing.

Their business strategy is to form partnerships to support and expand their clinical programs and commercial opportunities and to build a diverse portfolio of oncology product candidates. As part of this strategy, they are collaborating with the Scripps Florida Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors as therapeutic agents to treat cancer.

They would also like to explore potential partnership opportunities for co-development and commercialization of their lead product candidate, Picoplatin in Europe. Picoplatin is a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. It is currently being studied in clinical trials for treatment of small cell lung, colorectal and hormone-refractory prostate cancers.

Their focus is to seek small molecule product opportunities in preclinical and early clinical development (lead optimization to phase I/II) that are aligned with their therapeutic focus in oncology. Molecules should have good oral potential and includes natural products analogues as well.

URL

Your Feedback

back